Teriflunomide: an oral therapy for first-line treatment of children and adolescents living with relapsing-remitting multiple sclerosis

References

• Boiko A, Vorobeychik G, Paty D, et al. Early onset multiple sclerosis: a longitudinal study. Neurology. 2002;59(7):1006–1010. doi: 10.1212/WNL.59.7.1006
   PubMed Web of Science ®Google Scholar
• Renoux C, Vukusic S, Mikaeloff Y, et al. Natural history of multiple sclerosis with childhood onset. N Engl J Med. 2007;356(25):2603–2613. doi: 10.1056/NEJMoa067597
   PubMed Web of Science ®Google Scholar
• Gorman MP, Healy BC, Polgar-Turcsanyi M, et al. Increased relapse rate in pediatric-onset compared with adult-onset multiple sclerosis. Arch Neurol. 2009;66(1):54–59. doi: 10.1001/archneurol.2008.505
   PubMed Web of Science ®Google Scholar
• Pohl D, Waubant E, Banwell B, et al. Treatment of pediatric multiple sclerosis and variants. Neurology. 2007;68(Suppl Issue 16, Supplement 2):S54–S65. doi: 10.1212/01.wnl.0000259407.40023.ab
   PubMedGoogle Scholar
• Ghezzi A, Banwell B, Boyko A, et al. Meeting review: the management of multiple sclerosis in children: a European view. Mult Scler. 2010;16(10):1258–1267. doi: 10.1177/1352458510375568
   PubMed Web of Science ®Google Scholar
• Chitnis T, Tenembaum S, Banwell B, et al. Consensus statement: evaluation of new and existing therapeutics for pediatric multiple sclerosis. Mult Scler. 2012;18(1):116–127. doi: 10.1177/1352458511430704
   PubMed Web of Science ®Google Scholar
• Dell’avvento S, Sotgiu MA, Manca S 3, et al. Epidemiology of multiple sclerosis in the pediatric population of Sardinia, Italy. Eur J Pediatr. 2016;175(1):19–29. doi: 10.1007/s00431-015-2588-3
   PubMed Web of Science ®Google Scholar
• Langer-Gould A, Zhang JL, Chung J, et al. Incidence of acquired CNS demyelinating syndromes in a multiethnic cohort of children. Neurology. 2011;77(12):1143–1148. doi: 10.1212/WNL.0b013e31822facdd
   PubMed Web of Science ®Google Scholar
• Ghezzi A, Deplano V, Faroni J, et al. Multiple sclerosis in childhood: clinical features of 149 cases. Mult Scler. 1997;3(1):43–46. doi: 10.1177/135245859700300105
   PubMed Web of Science ®Google Scholar
• Deryck O, Ketelaer P, Dubois B. Clinical characteristics and long term prognosis in early onset multiple sclerosis. J Neurol. 2006;253(6):720–723. doi: 10.1007/s00415-006-0095-1
   PubMed Web of Science ®Google Scholar
• Alroughani R, Akhtar S, Ahmed SF, et al. Incidence and prevalence of pediatric onset multiple sclerosis in Kuwait: 1994-2013. J Neurol Sci. 2015;353(1–2):107–110. doi: 10.1016/j.jns.2015.04.025
   PubMed Web of Science ®Google Scholar
• Banwell B, Krupp L, Kennedy J, et al. Clinical features and viral serologies in children with multiple sclerosis: a multinational observational study. Lancet Neurol. 2007;6(9):773–781. doi: 10.1016/S1474-4422(07)70196-5
   PubMed Web of Science ®Google Scholar
• Boiko AN, Gusev EI, Sudomoina MA, et al. Association and linkage of juvenile MS with HLA-DR2(15) in Russians. Neurology. 2002;58(4):658–660. doi: 10.1212/WNL.58.4.658
   PubMed Web of Science ®Google Scholar
• Yeh EA, Chitnis T, Krupp L, et al. Pediatric multiple sclerosis. Nat Rev Neurol. 2009;5(11):621–631. doi: 10.1038/nrneurol.2009.158
   PubMed Web of Science ®Google Scholar
• Amato MP, Goretti B, Ghezzi A, et al. Cognitive and psychosocial features of childhood and juvenile MS. Neurology. 2008;70(20):1891–1897. doi: 10.1212/01.wnl.0000312276.23177.fa
   PubMed Web of Science ®Google Scholar
• Amato MP, Goretti B, Ghezzi A, et al. Cognitive and psychosocial features in childhood and juvenile MS: two-year follow-up. Neurology. 2010;75(13):1134–1140. doi: 10.1212/WNL.0b013e3181f4d821
   PubMed Web of Science ®Google Scholar
• Amato MP, Goretti B, Ghezzi A, et al. Neuropsychological features in childhood and juvenile multiple sclerosis: five-year follow-up. Neurology. 2014;83(16):1432–1438. doi: 10.1212/WNL.0000000000000885
   PubMed Web of Science ®Google Scholar
• Chitnis T, Krupp L, Yeh A, et al. Pediatric multiple sclerosis. Neurol Clin. 2011;29(2):481–505. doi: 10.1016/j.ncl.2011.01.004
   PubMed Web of Science ®Google Scholar
• Pfeifenbring S, Bunyan RF, Metz I, et al. Extensive acute axonal damage in pediatric multiple sclerosis lesions. Ann Neurol. 2015;77(4):655–667. doi: 10.1002/ana.24364
   PubMed Web of Science ®Google Scholar
• Banwell B, Reder AT, Krupp L, et al. Safety and tolerability of interferon beta-1b in pediatric multiple sclerosis. Neurology. 2006;66(4):472–476. doi: 10.1212/01.wnl.0000198257.52512.1a
   PubMed Web of Science ®Google Scholar
• Tenembaum SN, Banwell B, Pohl D, et al. Subcutaneous interferon Beta-1a in pediatric multiple sclerosis: a retrospective study. J Child Neurol. 2013;28(7):849–856. doi: 10.1177/0883073813488828
   PubMed Web of Science ®Google Scholar
• Narula S, Hopkins SE, Banwell B. Treatment of pediatric multiple sclerosis. 39. Curr Treat Options Neurol. 2015;17(3):336. doi: 10.1007/s11940-014-0336-z
   PubMed Web of Science ®Google Scholar
• Yeh EA, Waubant E, Krupp LB, et al. Multiple sclerosis therapies in pediatric patients with refractory multiple sclerosis. Arch Neurol. 2011;68(4):437–444. doi: 10.1001/archneurol.2010.325
   PubMed Web of Science ®Google Scholar
• Baroncini D, Zaffaroni M, Moiola L, et al. Long-term follow-up of pediatric MS patients starting treatment with injectable first-line agents: a multicentre, Italian, retrospective, observational study. Mult Scler J. 2019;25(3):399–407. doi: 10.1177/13524585187543641
   PubMed Web of Science ®Google Scholar
• Schwartz CE, Grover SA, Powell VE, et al. Risk factors for non-adherence to disease-modifying therapy in pediatric multiple sclerosis. Mult Scler. 2018;24(2):175–185. doi: 10.1177/1352458517695469
   PubMed Web of Science ®Google Scholar
• Ghezzi A, Moiola L, Pozzilli C, et al. Natalizumab in the pediatric MS population: results of the Italian registry. BMC neurol. 2015;15(1):174. doi: 10.1186/s12883-015-0433-y4
   PubMedGoogle Scholar
• Chitnis T, Arnold DL, Banwell B, et al. Trial of fingolimod vs. interferon beta-1a in pediatric multiple sclerosis. N Engl J Med. 2018;379(11):1017–1027. doi: 10.1056/NEJMoa1800149
   PubMed Web of Science ®Google Scholar
• FDA. Aubagio (teriflunomide) prescribing information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202992s000lbl.pdf (Accessed on Jan 23, 2023).
   Google Scholar
• EMA. Aubagio (teriflunomide) summary of product characteristics. Available at: https://www.ema.europa.eu/en/documents/product-information/aubagio-epar-product-information_en.pdf (Accessed on Jan 23, 2023)
   Google Scholar
• Bar-Or A, Pachner A, Menguy-Vacheron F, et al. Teriflunomide and its mechanism of action in multiple sclerosis. Drugs. 2014;74(6):659–674. doi: 10.1007/s40265-014-0225-5
   PubMed Web of Science ®Google Scholar
• Li R, Rezk A, Miyazaki Y, et al. Proinflammatory GM-CSF–producing B cells in multiple sclerosis and B cell depletion therapy. Sci Transl Med. 2015;7(310):310ra166. doi: 10.1126/scitranslmed.aab4176
   PubMed Web of Science ®Google Scholar
• O’Connor P, Wolinsky JS, Confavreux C, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med. 2011;365(14):1293–1303. doi: 10.1056/NEJMoa1014656
   PubMed Web of Science ®Google Scholar
• Confavreux C, O’Connor P, Comi G, et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2014;13(3):247–256. doi: 10.1016/S1474-4422(13)70308-9
   PubMed Web of Science ®Google Scholar
• Miller AE, O’Connor P, Wolinsky JS, et al. Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis. Mult Scler. 2012;18(11):1625–1632. doi: 10.1177/1352458512446044
   PubMed Web of Science ®Google Scholar
• Butzkueven H, Kappos L, Pellegrini F, et al. A serial in vivo 7T magnetic resonance phase imaging study of white matter lesions in multiple sclerosis. Mult Scler. 2013;19(1):69–80. doi: 10.1177/1352458512447196
   PubMed Web of Science ®Google Scholar
• Hauser SL, Bar-Or A, Comi G, et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med. 2017;376(3):221–234. doi: 10.1056/NEJMoa1601277
   PubMed Web of Science ®Google Scholar
• Kappos L, Fox RJ, Burcklen M, et al. Ponesimod compared with teriflunomide in patients with relapsing multiple sclerosis in the active-comparator phase 3 OPTIMUM study a randomized clinical trial. JAMA Neurol. 2021;78(5):558–567. doi: 10.1001/jamaneurol.2021.0405
   PubMed Web of Science ®Google Scholar
• Steinman L, Fox E, Hartung HP, et al. Ublituximab versus teriflunomide in relapsing multiple sclerosis. N Engl J Med. 2022;387(8):704–714. doi: 10.1056/NEJMoa2201904
   PubMed Web of Science ®Google Scholar
• Zarei M, Fereshtehnejad SM, Dastoorpoor M, et al. Teriflunomide in relapsing-remitting multiple sclerosis: a systematic review and meta-analysis of randomized controlled trials. J Neurol. 2018;265:307–316. doi: 10.1007/s00415-017-8693-y
   Google Scholar
• Hestvik ALK, Frederiksen J, Nielsen HH, et al. Real-world study of relapsing-remitting multiple sclerosis patients treated with Teriflunomide in Nordic countries: quality-Of-Life, efficacy, safety and adherence outcomes. MS RelDis. 2022;63:103892. doi: 10.1016/j.msard.2022.103892
   Google Scholar
• Dardiotis E, Perpati G, Borsos, et al. Real-World Assessment of Quality of Life in Patients with Relapsing Remitting Multiple Sclerosis Treated with Teriflunomide for Two Years: patient-Reported Outcomes from the AURELIO Study in Greece. Neurol Ther. 2022;11(3):1375–1390. doi: 10.1007/s40120-022-00384-2
   PubMed Web of Science ®Google Scholar
• Hardy TA, Parratt J, Beadnall H, et al. Treatment satisfaction in patients with relapsing-remitting multiple sclerosis initiated on teriflunomide in routine clinical practice: Australian observational data. BMJ Neurol Open. 2022 Jul 4;4(2):e000315. eCollection 2022.PMID: 35865788. doi: 10.1136/bmjno-2022-000315
   PubMedGoogle Scholar
• Chitnis T, Banwell B, Kappos L, et al. TERIKIDS Investigators. Safety and efficacy of teriflunomide in paediatric multiple sclerosis (TERIKIDS): a multicentre, double-blind, phase 3, randomised, placebo-controlled trial. Lancet Neurol. 2021 Dec;20(12):1001–1011. PMID: 34767512. doi: 10.1016/S1474-4422(21)00364-1
   PubMed Web of Science ®Google Scholar
• Bovis F, Ponzano M, Signori A, et al. Reinterpreting Clinical Trials in Children with Multiple Sclerosis Using a Bayesian Approach. JAMA Neurol. 2022;79(8):821–822. doi: 10.1001/jamaneurol.2022.1735
   PubMed Web of Science ®Google Scholar
• Kuhle J, Chitnis T, Banwell B, et al. Plasma neurofilament light chain in children with relapsing MS receiving teriflunomide or placebo: a post hoc analysis of the randomized TERIKIDS trial. Mult Scler. 2023 Jan;12(3):385–394. Online ahead of print. PMID: 35189351. doi: 10.1177/13524585221144742
   Google Scholar
• Paik J. Teriflunomide: pediatric First Approval. Paediatr Drugs. Pediatr Drugs. 2021 Nov;23(6):609–613. PMID: 3459569. doi: 10.1007/s40272-021-00471-1
   PubMed Web of Science ®Google Scholar
• Krysko KM, Graves JS, Rensel M, et al. Real-world effectiveness of initial disease-modifying therapies in pediatric multiple sclerosis. Ann Neurol. 2020;88(1):42–55. doi: 10.1002/ana.25737
   PubMed Web of Science ®Google Scholar
• Solmaz I, Acar Ozen P, Parlak S, et al. Newer disease modifying treatments in pediatric onset multiple sclerosis: experience from a single center. Eur J Paediatr Neurol. 2022 Jul 39:110–115. doi: 10.1016/j.ejpn.2022.06.013
   PubMed Web of Science ®Google Scholar
• Krysko KM, Graves J, Rensel M, et al. Use of newer disease-modifying therapies in pediatric multiple sclerosis in the US. Neurology. 2018;91(19):e1778–e1787. doi: 10.1212/WNL.0000000000006471
   PubMed Web of Science ®Google Scholar
• Kalincik T, Havrdova EK, Horakova D. Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis. J Neurol Neuros Psychiat. 2019 Epub 2019 Jan 13;90(4):458–468. doi: 10.1136/jnnp-2018-319831
   PubMed Web of Science ®Google Scholar
• Nixon R, Bergvall N, Tomic D, et al. No evidence of disease activity: indirect comparisons of oral therapies for the treatment of relapsing-remitting multiple sclerosis. Adv Ther. 2014 Nov;31(11):1134–1154.
   PubMed Web of Science ®Google Scholar